Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin, Metformin, and Dapagliflozin in NAFLD/MASLD
NCT07338331Completed
- Sponsor
- Galala University
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of aspirin, dapagliflozin and liquid metformin (Aspargo Labs) in non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Galala University. Primary endpoints: Lipid Profile Parameters at 6 months, Controlled Attenuation Parameter at 6 months and 2 more. Started Apr 2023; status: completed.
02
Drugs
aspirindapagliflozinliquid metformin (Aspargo Labs)
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT07338331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07338331.